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Abstract 
Background: Leukemic and mesenchymal stem cells interact in the leukemic microenvironment and affect each 
other differently. This interplay has also important implications for the hematopoietic stem cell (HSC) biology and 
function. This study evaluated human HSC self‑renewal potential and quiescence in an in vitro leukemic niche with‑
out leukemic cells.
Methods: A leukemic niche was established by co‑culturing mesenchymal stem cells with a fresh conditioned 
medium obtained from a leukemic (REH) cell line. After 3 days, the REH‑conditioned medium was removed and 
freshly isolated CD34+ at a density of up to 100,000 cells/ml were added to the leukemic niche. CD34+ cell evalua‑
tions (cell cycle, self‑renewal gene expression and migration capacity) were performed after 3 further days of co‑
culture. Additionally, we preliminary investigated the soluble factors present in the leukemic niche and their effect 
on the mesenchymal stem cells. Statistical significance was assessed by Student’s t test or the nonparametric test 
Kolmogorov–Smirnov.
Results: By co‑culturing normal mesenchymal stem cells with the REH‑conditioned medium we showed that 
hematopoietic stem cells, normally in a quiescent state, enter cell cycle and proliferate. This loss of quiescence was 
accompanied by an increased expression of Ki‑67 and c‑Myc, two well‑known cell proliferation‑associated markers. 
Two central regulators of quiescence GATA2 and p53 were also down regulated. Importantly, two genes involved 
in HSC self‑renewal, Klf4 and the histone–lysine N‑methyltransferase enzyme Ezh2, were severely affected. On the 
contrary, c‑Kit expression, the stem cell factor receptor, was upregulated in hematopoietic stem cells when compared 
to the normal niche. Interestingly, mesenchymal stem cells incubated with the REH‑conditioned medium stopped 
growing, showed a flattened morphology with the appearance of small vacuoles, and importantly, became positive 
for the senescence‑associated beta‑galactosidase activity. Evaluation of the leukemic‑conditioned medium showed 
increased IL‑6 and IL‑8, suggesting that these cytokines could be responsible for the observed changes.
Conclusions: Our results showed that quiescence and self‑renewal are severely affected in this leukemic niche. This 
in vitro leukemic niche, established without leukemic cells, will facilitate HSC gene expression evaluation and the 
development of therapeutic agents aimed to neutralize soluble factors and the cell signaling pathways involved in 
HSC alterations.
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Background
Hematopoietic stem cells (HSC) are characterized by 
their self-renewal and multipotent differentiation capaci-
ties. These properties are necessary for the maintenance 
of the HSC pool and important in the development and 
regeneration of the hematopoietic system under normal 
and stressful conditions [1–3]. HSC reside in special-
ized niches [4] in the bone marrow (BM) with which they 
interact continuously, influencing these properties [5, 6]. 
Multiple cellular types, soluble factors and extracellular 
matrix components form this niche [7, 8]. Nevertheless, 
a predominant role is played by the mesenchymal stem 
cells (MSC) due to their multilineage differentiation 
capacity and their regulation of HSC function [9, 10].
Under homeostatic conditions, most HSC exist in the 
G0 phase of the cell cycle with signals from the niche 
used to preserve a quiescent state as a protective mecha-
nism against cell damage and exhaustion [6]. Other sig-
nals stimulate the appearance of cell progenitors and thus 
cell cycle entry and proliferation [11]. In purified mouse 
stem and progenitors cells the molecular network regu-
lating self-renewal, differentiation and the maintenance 
of quiescence has been identified [12]. These authors 
have shown that the long-term engraftment potential 
resides mainly in the G0 cell fraction. Therefore, a qui-
escent state is fundamental for preserving key functional 
features necessary for transplantation. In humans, it has 
been shown that HSC in the G0 phase have better adher-
ence to MSC [13] and we have previously shown that 
primitive HSC in co-culture with MSC induce a VCAM-
dependent pro-migratory phenotype [14], suggesting 
that the G0 cell fraction has better BM homing efficiency. 
Importantly, the relationship between cell cycle regula-
tors (cytokines, cyclin and cyclin-regulators, transcrip-
tion factors, microRNA, etc.) and HSC self-renewal has 
been partially elucidated [5, 15].
The extracellular signals responsible for HSC mainte-
nance and survival are well known. SCF/c-Kit, Ang-1/
Tie1/2 and TPO/c-MPL signaling is essential for main-
taining HSC quiescence, survival and function [1, 16–
18]. Also, it has been reported that the SDF-1/CXCL12 
chemokine acts not only as an essential chemoattract-
ant for HSC homing but also as a regulator of HSC qui-
escence [19]. Likewise, SDF-1/CXCL12 is an inhibitor 
of human long-term culture-initiating cell cycling and 
therefore its reduction in the BM induces cell cycling 
[20]. Abnormal stimulation of these receptors could 
induce HSC cycling and exhaustion [21]. HSC prolifera-
tion can also be induced in  situations of hematopoietic 
challenge, i.e., infection/inflammation, senescence, leuke-
mia, chemotherapy, irradiation and BM transplantation, 
among others [22–24].
Likewise, early work has shown that BM stimuli are 
also essential for leukemic cell growth and expansion 
[25] and that leukemic cell growth affects HSC func-
tion both in  vivo and in  vitro [26]. Recently, it has also 
been shown in mouse models, that the BM niche pro-
tects leukemic cells against chemotherapy, and that the 
leukemic-induced decrease in SDF-1 levels is responsible 
for impaired human CD34+ homing and retention [27, 
28]. All these results suggest that the microenvironment 
that supports leukemic cells and affects HSC proper-
ties [12] could be a valid target for chemotherapeutic 
intervention.
In the present study, we were interested in the evalua-
tion of human HSC self-renewal potential and cell cycle 
regulation in an in  vitro leukemic niche. By incubation 
of MSC with a leukemic-conditioned medium, obtained 
from an acute lymphocytic leukemia pre-B (ALL-B) cell 
line (REH), we were able to study gene expression of 
some important molecules involved in HSC function. 
In this system, HSC showed increased cell proliferation 
and gene expression changes compatible with loss of self-
renewing potential. These alterations are equivalent to 
the observed reduced hematopoiesis, accompanied by an 
increase in progenitors and differentiated cells, seen in 
patients with ALL [29].
Methods
Isolation of CD34+ from umbilical cord blood (UCB)
UCB samples were obtained from normal full-term deliv-
eries. Mononuclear cells (MNC) were isolated by Ficoll-
Hypaque density gradient centrifugation and CD34+ 
cells were purified using a MACS CD34+ isolation kit 
(Miltenyi Biotec, Auburn, CA, USA). Cell purity was 
evaluated by flow cytometry using allophycocyanin anti-
CD34 (Clone AC136, Miltenyi Biotec) and cell viability 
by Trypan blue dye exclusion.
Isolation and characterization of BM‑MSC
BM-MSC were isolated from BM aspirates of healthy 
young donors. MSC were cultured, expanded and char-
acterized according to the criteria established by the 
International Society for Cell Therapy (cell morphology, 
expression of cell surface markers and the ability to dif-
ferentiate into osteoblasts, chondrocytes and adipocytes) 
[30]. After the 3rd passage, adherent cells were trypsinized 
and labeled with the following monoclonal antibodies: PE 
mouse anti-human CD73 (clone AD2, BD Pharmingen), 
APC mouse anti-human CD105 (clone 43A4E1, Milte-
nyi Biotec), PerCP mouse anti-human CD45 (clone 2D1, 
BD Biosciences), FITC mouse anti-human CD90 (clone 
F15-42-1, Abcam), APC mouse anti-human CD34 (clone 
AC136, Miltenyi Biotec) and FITC mouse anti-human 
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CD44 (clone MEM-85, Invitrogen). Data were acquired 
using a FACSAria II flow cytometer (BD Biosciences, San 
Jose, CA, USA). FACS Diva software, CellQUEST PRO 
software, FlowJo, and Paint-a-Gate software (BD Bio-
sciences) were used for data analysis.
The mesenchymal lineages differentiation capacity of 
MSC was determined using specific staining and micro-
scopic observation, as previously described [31]. Briefly, 
3rd passage 2 × 104 MSC were cultured in a 24-well plate 
in IMDM until they reached confluence. For adipogenic 
differentiation, cells were cultured for 3  days in induc-
tion medium (MEMα supplemented with 10% FBS, 1 mM 
dexamethasone, 0.5 mM isobutylmethylxanthine, 200 μM 
indomethacin, and 10  μg/ml insulin, all reagents from 
Sigma Aldrich) followed by incubation in maintenance 
medium (MEMα, supplemented with 10% FBS and 10 μg/
ml insulin) for 3 days, and these treatments were repeated 
twice. Osteogenic differentiation was induced by incuba-
tion with the induction medium MEMα supplemented 
with 10% FBS, 100  nM dexamethasone, 0.2  mM ascor-
bic  acid  2-phosphate, and 10  mM β-glycerophosphate 
(all reagents from Sigma Aldrich) for 2  weeks. Finally, 
for chondrogenic differentiation, cells were plated and 
cultured in a chondrogenic induction medium (MEMα 
and 10 ng/ml TGFβ-1, Sigma Aldrich) for 2 weeks. Cells 
were washed with PBS 1X, formalin fixed, and stained 
with 0.35% Oil Red O solution (Sigma Aldrich) for adipo-
genic differentiation, alkaline phosphatase (AP staining 
kit, Chemicon Int.) for osteogenic differentiation, or with 
0.1% Safranin O (Sigma Aldrich) for chondrogenic differ-
entiation. Cells were examined under an inverted micro-
scope (Nikon, Model TS-100) and photographed with 
a Canon Power Shot A460, Zoom Browser EX software. 
Characterized MSC were expanded, frozen and used for 
the different experiments in passages 3–5.
REH‑conditioned medium (REH‑CM) preparation
2.5  ×  105 REH cells/ml were cultured in RPMI Glu-
tamax-I (GIBCO, Invitrogen) supplemented with 1% 
sodium pyruvate, 1% MEM non-essential amino acid 
solution 100× and 1% FBS for 24 h at 37 °C and 5% CO2 
in 75 cm2 culture flask. Next, REH cells were centrifuged 
at 500g ×  7  min, the supernatant was collected and fil-
tered through a 0.22 µm pore membrane filter and used 
fresh in all experiments.
Establishment of the leukemic niche (LN)
BM-MSC at 80% confluence were co-cultured for 3 days 
with fresh REH-CM (with a re-feeding after 1.5  days). 
After REH-CM addition MSC stopped dividing and 
did not further increase cell number (not shown). After 
3 days, the REH-CM was gently removed from the wells 
and freshly isolated CD34+ at a density of up to 100,000 
cells/ml were added to these MSC. For the establish-
ment of the so-called normal niche (NN), MSC were set 
at a lower density in order to have 80% confluence after 
3  days of culture [31]. The idea was to have both NNs 
and LN with MSC at 80% confluence when the CD34+ 
cells were added. Freshly isolated CD34+, from the same 
UCB used for the LN, were layered over MSC at the same 
80% confluence but at two fetal bovine serum (FBS) con-
centration, 10% (NN10) or 1% (NN1). A fraction of these 
CD34+ cells was kept for evaluation in each experi-
ment (freshly isolated CD34+ cells). CD34+ cell evalu-
ation in the different niches was done after 3 days of the 
co-culture.
Cytometric bead array (CBA) determination of cytokines
For the determination of the human pro-inflammatory 
cytokines concentration in the supernatant of the dif-
ferent cultures we have used the cytometric bead array 
kit (Becton–Dickinson Biosciences) for human inflam-
matory cytokines, following the manufacturer’s instruc-
tions. Supernatants were obtained from MSC after 3 days 
of culture in IMDM supplemented with 10% FBS, 1% 
sodium pyruvate, 1% MEM Non- Essential Amino Acids 
(GIBCO, Invitrogen); MSC cultured in the same condi-
tions except for 1% FBS; REH cells cultured in RPMI 1640 
supplemented with 10% FBS, 1% sodium pyruvate, 1% 
MEM non-essential amino acids (GIBCO, Invitrogen); 
REH-CM prepared as indicated above; and co-cultures 
of MSC with REH cells, and MSC cells with REH-CM. 
Cytokines concentration was evaluated by flow cytome-
try (FACSAriaTM II). Flow Jo and FCAP Array v3.0 Soft-
ware (Becton–Dickinson Biosciences) were used for data 
analysis.
Cell cycle analysis by flow cytometry
For cell cycle analysis, freshly isolated CD34+ cells and 
CD34+ cells obtained from both the NN and the LN 
after co-culturing with MSC for 3  days were fixed with 
4% formaldehyde and permeabilized with 0.1% Triton 
X-100. The cells were stained for 30  min at room tem-
perature with the monoclonal antibody APC-conju-
gated anti-human Ki67 (clone Ki67, Biolegend) and/or 
incubated with Hoechst 33342 (2′-[4-ethoxyphenyl]-5-
[4-methyl-1-piperazinyl]-2,5′-bi-1H-benzimidazole tri-
hydrochloride trihydrate) (from Invitrogen) (2n DNA 
content, G0/G1; >2n DNA content, S-G2-M) for 45 min 
at 37 °C. Finally, the supernatants were removed and cells 
were resuspended in PBS 1X for flow cytometry evalua-
tion (FACSAriaTM II, BD Biosciences). FlowJo and FCS 
Express Flow Cytometry Data Analysis Softwares v5.0 
(BD Biosciences) were used for data analysis.
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Gene expression analysis by real time‑PCR‑SYBR green
Freshly isolated CD34+ cells and CD34+ cells obtained 
from the NN or the LN were washed in PBS and total 
RNA was extracted with TRIzol reagent (Invitrogen). 
The RNA obtained was quantified by fluorogenic meth-
ods (NanoDrop 2000C, Thermo Scientific) and stored 
at −70 °C until analysis; A qualitative assessment by 1% 
agarose gel electrophoresis was performed. Eventual 
contamination by genomic DNA was removed by using 
the DNAse I Kit (Invitrogen). Reverse transcription was 
performed using the High Capacity Kit (Applied Biosys-
tems) from 1000 ng RNA. qRT-PCR was performed on a 
7500 real time PCR Systems (Applied Biosystems®) with 
the SYBR Green Master Mix (Applied Biosystems). The 
reactions were done in triplicate for each sample and in 
three independent experiments. The total reaction vol-
ume was 20  μl (including 0.5  μl cDNA, SYBR Green, 
and 0.1 mM of primers, see Additional file 1: Table S1). 
Relative gene expression levels were normalized to RPS18 
transcript levels and calculated using the 2−∆∆CT method. 
A “screening” of 19 selected genes was performed. The 
sequences of the primers were determined using Basic 
Local Alignment Search Tool (BLAST) based on previ-
ous publications; Forward and reverse primers used are 
shown in Additional file 1: Table S1.
Senescence‑associated β‑galactosidase (SA‑βGAL) 
evaluation in MSC
Senescence-associated β-galactosidase (SA-βGAL) activ-
ity was evaluated in MSC after incubation with the REH-
CM in the same conditions as described above. For this 
purpose we have used the cellular senescence assay kit 
(KAA002, Millipore). Briefly, MSC were seeded in dupli-
cates in 24-well plates, washed twice with PBS 1X, and 
then fixed with formalin for 10 min at room temperature. 
Next, MSC were washed with PBS 1X and incubated 
over-night at 37  °C with the β-gal substrate in an acidic 
buffer (pH 6.0) and examined with an inverted micro-
scope (Nikon, Model TS-100) and photographed (Canon 
Power Shot A460, Zoom Browser EX software). The 
appearance of development of a perinuclear blue color 
was an indication of senescence.
HSC migration evaluation
Transwell filters (Corning Costar) with 5  μm pore size, 
6.5  mm diameter, inserted in a 24-well plate (Corning) 
were incubated for 1 h at 37 °C with the migration buffer 
(RPMI-1640 and 2% BSA). Then 5 × 104 HSC from the 
NN10, NN1 and LN in 100 μl were added to the upper 
chamber. The lower chambers were filled with 600  μl 
of migration buffer containing recombinant human 
stromal derived factor-1 (rhSDF-1a, Miltenyi Biotec) 
at 100 ng/ml. After 4 h at 37  °C in a 5% CO2 incubator, 
cells that migrated to the lower chamber were har-
vested and counted with a FACSAria II flow cytometer 
(BD Biosciences, San Jose, CA, USA). The numbers of 
migrated cells were normalized to unstimulated controls 
(FACS acquisition was performed in duplicate in some 
experiments).
Statistical analysis
All data are presented as mean  +  SEM. Statistical sig-
nificance was assessed by Student’s t test or the nonpara-
metric test Kolmogorov–Smirnov to compare cumulative 




We have established an in vitro LN by incubation of MSC 
(Additional file  2: Figure S1A, B) with a REH-CM dur-
ing 3 days. We have previously determined that this LN 
correctly simulated a LN set with REH cells in the same 
conditions (not shown). In this latter niche, REH cells 
were very difficult to be detached from the MSC and 
therefore accurately molecular evaluation of HSC after 
co-incubation was difficult specially if RNA extracts for 
gene expression analysis have to be prepared. Therefore 
the setting of a leukemic niche without leukemic cells 
was essential to study gene expression in HSC in a LN. 
Re-feeding with fresh REH-CM was done during the 
incubation period to ensure a proper and permanent 
exposure to soluble factors, simulating permanent REH 
cell secretion. After 3  days of incubation, the REH-CM 
was removed and freshly isolated CD34+ HSC (>95% 
purity and >95% cell viability) (Additional file  2: Figure 
S1C) were added for additional 3 days, after which HSC 
evaluations were performed. As controls, HSC co-cul-
tured with MSC at the same cell confluence and in nor-
mal culture medium with 10% FBS (NN10) or 1% FBS 
(NN1) were performed. For comparison, HSC evalua-
tions from freshly isolated HSC were also performed in 
each experiment.
CD34+ cell proliferation in the LN
We first analyzed Hoechst 33342 staining in freshly iso-
lated HSC and HSC obtained from the different niches 
(NN10, NN1 and LN). In freshly isolated cells, almost 
the entire population (99.6%) was in the G0/G1 phase 
(Fig. 1a) while in the NN10 and N1 this population was 
near 70% (Fig.  1b, c). As expected, lowering FBS con-
centration reduced cells in the S- and G2/M phases. 
Interestingly, we observed a slight increase in the S/
G2/M population in HSC obtained from the LN when 
compared to the NNs (24 vs 17% in NN1 and vs 19.5% 
in NN10). Considering that after this short period of 
Page 5 of 11Vanegas and Vernot  Exp Hematol Oncol  (2017) 6:2 
time (3  days) it is not possible to see big differences in 
proliferation due to the population doubling (PD) time 
of HSC in co-culture with MSC, the proliferation-asso-
ciated nuclear antigen Ki-67 was therefore evaluated. A 
clear increase of Ki67 in HSC from the LN was observed, 
while no differences were seen between NN10 and NN1 
(Fig. 2a, b). Double labeling with anti-Ki67 and Hoechst 
33342 showed clearly that the G0/G1 subpopulation was 
reduced in the LN compared to NNs (23% vs about 60%, 
respectively) (Additional file  3: Figure S2). Addition-
ally, the G0 cell subpopulation was reduced in the LN as 
evaluated by the Ki67 low-expressing cells in the GO/G1 
gate. Furthermore, c-Myc expression, a proliferation- and 
progenitor differentiation-associated transcription factor 
[32] was increased in the LN (Fig. 2c). Thus, HSC in the 
LN enter the cell cycle and proliferate, suggesting that the 
control over cell proliferation, normally exerted by the 
MSC, is lost in this condition.
GATA2 y p53 expression in HSC in the LN
GATA2 and p53, having overlapped expression pat-
terns [33], are believed to be central regulators of the 
hematopoietic homeostasis, in special of the HSC quies-
cence. GATA2 and p53 were expressed in freshly isolated 
HSC and were not or very low expressed in MSC (Fig. 3a, 
b) or REH cells (not shown). Compared to NN10, HSC 
from the LN showed lower GATA2 expression, while no 
differences were found between NN1 and LN (Fig.  3a). 
On the contrary, p53 expression was severely reduced 
in the LN compared to freshly isolated HSC or HSC 
obtained form NN10 or NN1 (Fig. 3b).
Expression of genes involved in self‑renewal
We have also performed a gene expression analysis of 
other 15 genes supposed to be involved in HSC self-
renewal, including Runx1, FoxO3a, SMAD4, Angpt1, 
Tie2, p16, Notch1, Bmi-1, HoxB4, OCT4 and Nanog [5, 
6, 34–38]. None of these 12 genes showed differences 
in expression between the NN and the LN. Only three 
genes were differentially expressed in the NN and the 
LN. Ezh2, a histone–lysine N-methyltransferase enzyme, 
and Klf4, a reprogramming transcription factor, showed 
both a lower expression in the LN compared to NN10 
(Fig.  4a, b). No differences in Ezh2 and Klf4 expression 
Fig. 1 The LN induces increases in the S + G2/M phases of the cell cycle in HSC. Freshly isolated HSC (a) or HSC from the different niches (b NN10, 
c NN1, d LN) were stained with Hoechst 33342 dye for cell cycle evaluation by flow cytometry (FACSAriaTM II, BD Biosciences). Areas under the 
histograms were used to determine the percentage of cells in sub‑G0, G0/G1, S and G2/M phases of the cell cycle. FlowJo and FCS Express Flow 
Cytometry Data Analysis Softwares v5.0 (BD Biosciences) were used for data analysis. A representative experiment is shown
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between NN10 and freshly isolated HSC were observed. 
On the contrary, cKit, the cell receptor for the SCF, had 
an increased expression (X2) in the LN compared to both 
NNs (Fig. 4c), but compared to freshly isolated HSC its 
expression was only one-third. Interestingly, these three 
genes were highly expressed in fresh HSC, suggesting 
that a leukemic microenvironment affect their expression 
importantly.
The LN induces senescence in MSC and lower migration 
in HSC
In the course of the different experiments we observed 
that after incubation with the REH-CM, MSC stopped 
dividing and looked flattened with the appearance of 
small vacuoles. We thus proceeded to evaluate the senes-
cent-associated β-galactosidase (SA-βGal) activity, which 
was positive after incubation with the leukemic-CM. 
Control MSC in culture medium were totally normal. 
This senescent-associated phenotype would explain in 
part, the loss of cell support of MSC to HSC (Fig.  5a). 
Since cell cycle entry affects HSC migration capacity [39] 
we have also study the effect of the LN in HSC migration 
using a transwell system. Consistently, HSC from the LN 
migrated less toward SDF-1 (Fig.  5b), showing another 
functional alteration of HSC in the LN that could be rel-
evant in vivo.
Partial REH‑CM characterization
Since senescence and inflammation are two related pro-
cesses relevant to tumor growth and progression [40], we 
studied the inflammatory cytokines that may be present 
in the LN and responsible for the effects observed in HSC 
in the LN. Using a CBA assay we were able to show that 
IL-6 and IL-8 were the most abundant pro-inflammatory 
cytokines present in the LN (Fig.  5c). These cytokines 
were not present in the REH-CM itself but were therefore 
Fig. 2 The LN increases proliferation of HSC. HSC proliferation, from the different niches as indicated, was evaluated by labelling cells with anti‑Ki67 
monoclonal antibody conjugated to FITC by flow cytometry (FACSAriaTM II, BD Bioscience). a Representative histogram showing fluorescence 
intensity of Ki‑67. b Mean fluorescence intensity (MFI) quantification of HSC in NN10, NN1 and LN stained with anti‑Ki‑67 antibody. c qRT‑PCR for 
the evaluation of c‑Myc mRNA expression, as described in “Methods”. FlowJo was used for data analysis. Results shown are from two independent 
experiments done in duplicates. Error bars represent SEM *p < 0.05;**p < 0.01 (Student’s t test)
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produced by the MSC in the presence of REH-CM. Both 
cytokines were also induced in MSC by 10% SFB but only 
IL-6 was induced by 1% SFB. Interestingly, both IL-6 and 
IL-8 were also detected abundantly when the LN was set 
with REH cells (REH-LN in Fig. 5c), suggesting that our 
LN set by incubation of MSC with REH-CM simulates 
appropriately the leukemic microenvironment.
Discussion
Here we have shown that MSC control over HSC prolif-
eration is lost after incubation in a leukemic microenvi-
ronment. In a short period of incubation in the LN, HSC 
entered the S/G2/M phase of the cell cycle and increased 
Ki-67 and c-Myc expression, two well-known markers 
of cell proliferation. This suggests that HSC in the LN 
would be in a state prone to further increase prolifera-
tion. This is similar to what we have previously reported 
[31], showing that HSC, in co-culture with MSC, have a 
lower rate of proliferation than HSC cultured with MSC 
in the presence of early cytokines (TPO, Flt3L and SCF), 
strengthening the important role of soluble factors in 
HSC function. It has been reported that proliferating 
HSC differentiate into early progenitors [32] and that 
c-Myc expression is required for cell cycle progression 
and expansion, contrary to HSC that divide indepen-
dently of c-Myc. These results are consistent with ours, 
showing increased c-Myc expression in HSC in the LN.
Early work has suggested a potential link between 
GATA-2 and p53 pathways [33] and more recently it has 
been shown that GATA2 and p53 expression are essen-
tial regulators of HSC quiescence [41, 42]. Both genes 
were expressed in freshly isolated HSC and in the NN, 
but were down regulated in the LN, especially p53. This 
reduction in GATA2 and p53 would induce the loss of 
HSC quiescence, in agreement with the increased HSC 
proliferation observed above. Recently, it was shown 
that targeting p53 and GATA2 in leukemic stem cells 
led to synergistic leukemia cell killing without affecting 
normal HSC [43]. This could probably be explained by 
lower expression of p53 and GATA2 in HSC in the leuke-
mic microenvironment as found here in our in vitro LN 
model.
Also, it has been reported that fast-dividing cells have 
limited self-renewal and reconstitution capabilities [44, 
45]. We have also recently shown, that HSC in a leukemic 
microenvironment set with REH cells have decreased 
multipotency as evaluated by CFU assays (Vernot JP 
et  al. unpublished). To explore this issue in our LN, we 
studied genes involved in self-renewal. Unexpectedly, 
the majority of them were similarly expressed in the NNs 
and LN with only three genes differentially expressed 
in these in vitro culture systems. In particular, Klf4 was 
highly down regulated in the LN compared to HSC from 
NN or freshly isolated HSC. Also, it has been shown that 
Klf4 inhibits HSC proliferation by increasing the cell 
cycle inhibitors p21 and p27 and causing cell cycle arrest 
in vitro and in vivo [46]. Therefore, its down-regulation is 
also compatible with HSC increased proliferation. Ezh2 
was also down regulated in HSC obtained from the LN. 
It has been shown that Ezh2 is required for proper B 
and T cell development [47] suggesting that lower Ezh2 
expression would affect differentiation of both lympho-
cyte subpopulations, similar to the observed effect in leu-
kemia patients. Interestingly, Ezh2 inactivation has been 
also observed in leukemia [48] and Klf4 may function as 
a tumor suppressor gene in leukemia [49]. The third gene 
that we observed differentially expressed in these in vitro 
systems was c-Kit, the SCF receptor. Though, c-Kit was 
upregulated in HSC from the LN, but its expression 
was lower than in fresh HSC. SCF/c-Kit signaling is not 
only necessary for HSC viability [50], but also for HSC 
Fig. 3 Gata2 and p53 are down regulated in the LN. GATA2 and p53 
gene expression was analysed by qRT‑PCR in HSC from the different 
niches and compared to freshly isolated cells. RPS18 gene expres‑
sion was used to normalize data and samples were run in triplicates 
(n = 3). a Gata2 gene expression. b p53 gene expression. Data are 
shown as mean ± SEM. p values were calculated by paired Student’s t 
test, (ns: non‑significant, *p < 0.05, **p < 0.01)
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repopulation and self-renewal as evaluated in a non-
competitive transplantation assay [18] and for functional 
positioning HSC in the niche [51]. On the other hand, 
we have previously shown that lower c-Kit expression 
reduced HSC multipotency [31]. HSC migration was also 
affected in HSC obtained from the LN and this could be 
the consequence of altered adhesion to MSC [13]. Collec-
tively, our results showed that HSC in our in vitro LN lost 
quiescence, increased the proliferation rate, had reduced 
self-renewing potential and presented migration defects.
Since in our study we have set the LN without leu-
kemic cells, it is evident that soluble factors are respon-
sible for the observed effects. Our results showed that 
REH-secreted cytokines are indirectly responsible for 
the HSC malfunction. In fact, it seems that a senescence 
process is induced during the setting of the LN, and this 
is considerably affecting MSC soluble factor secretion. 
We have performed a preliminary characterization of the 
soluble factors that could be responsible of the observed 
effect in the LN. Interestingly, IL-6 and IL-8 were upregu-
lated in the LN but both cytokine were not present in the 
REH-CM itself, suggesting that their secretion by MSC 
is induced only by soluble factors secreted by the REH 
cells. Noteworthy, IL-6 and IL-8 levels increased in serum 
of leukemic patients and correlated with adverse clini-
cal effects and short survival [52, 53]. Consistently with 
this, IL-6 and IL-8 were also the major secreted cytokines 
found in a LN set directly with REH cells. The specific role 
of these two cytokines alone or together in MSC deserves 
further experiments. Our increased understanding of the 
Fig. 4 HSC from the LN have abnormal gene expression of molecules involved in self‑renewal. RT‑qPCR analysis of a Ezh2, b c‑Kit, c Klf4 gene 
expression in HSC co‑cultured with MSC and REH‑CM. Results are normalized to the housekeeping gene RPS18. Graphs show SEM; n = 3, ns: non‑
significant, *p < 0.05, **p < 0.01, ***p < 0.001 were calculated by using Student’s t test in GraphPad Prism5
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HSC alterations in the LN will foster studies owing to the 
development of novel therapeutic agents.
Conclusions
This study validates an in vitro leukemic niche established 
without leukemic cells to study HSC function, simulating 
a BM niche affected by the leukemic cells. We showed that 
HSC increased cell proliferation and presented changes 
in gene expression that are compatible with the loss of 
self-renewal potential. This is consistent with reports in 
patients with ALL, showing reduced hematopoiesis and 
increased numbers of progenitor and differentiated cells. 
We showed also that the leukemic microenvironment 
affected MSC and the soluble factors they secrete, simi-
lar to what has been described in patients with leukemia. 
This in vitro system, set without leukemic cells, may facili-
tate HSC evaluation and would be a valuable tool for the 
development of novel therapeutic agents.
Additional files
Additional file 1: Table S1. List of primers used for RT‑qPCR.
Additional file 2: Figure S1. Isolation and characterization of mesenchy‑
mal stem cells and hematopoietic stem cells. A. Flow cytometry analysis 
showing the expression of MSC surface markers (CD105, CD90, CD73, 
CD44) in the absence of CD45 and CD34 gene expression (not shown). 
The percentage of positivity for each marker is indicated. B. In vitro adipo‑, 
chondro‑ and osteogenic differentiation of BM MSC. C. CD34+ cells 
were isolated from human UCB by high‑gradient magnetic cell sorting. 
Evaluation of cell purity by flow cytometry of the CD34+ HSC (>90% in all 
experiments). Results shown are representative of one BM‑MSC and one 
UCB samples.
Additional file 3: Figure S2. Double labeling of HSC with Hoechst 
staining and anti‑Ki67 antibody after the co‑culture in the NN10, NN1 or 
LN. Dual‑parameter dot plot showing HSC staining with Hoechst and anti‑
Ki67 antibody, excluding dead cells. Cells in the G0 phase of the cell cycle 
(low Ki67 expression) appear at the bottom of the G0/G1 gate. Cells in the 
S/G2 + M phases were increased in the LN. A representative experiment 
is shown.
Fig. 5 REH‑CM increases SA‑βGAL activity in the BM‑MSC. a Representative SA‑β‑gal staining of BM MSC isolated from the NN10, NN1 and LN. 
b The chemotactic effect of SDF‑1 (100 ng/ml) on CD34+ HSC migration in the different niches was studied using a modified Boyden chamber 
assay. Results are expressed as the fold increase migration from two independent experiments done in duplicates. (ns: non‑significant, *p < 0.05, 
**p < 0.01). c Analysis of a multiplexed cytometric bead assay (CBA) of the LN. Cytokines (IL‑8, IL‑1B, IL‑6, IL‑10, TNFα and IL‑12p70) concentration in 
the samples was calculated from the data obtained by the FACS array
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